Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

ANAPTYSBIO, INC (ANAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab"
10/02/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update"
06/15/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K Quarterly results
Docs: "AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
02/10/2023 8-K Quarterly results
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6.2% stake in AnaptysBio Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 8.4% stake in ANAPTYSBIO, INC.
01/10/2023 4 Ware J. Anthony (Director) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 Topper James N (10% Owner) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 Schmid John P. (Director) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 RENTON HOLLINGS (Director) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 MULROY DENNIS (CFO) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 57,260 options to buy @ $23.23, valued at $1.3M
Granted 20,980 restricted stock units @ $0
01/10/2023 4 Marquet Magda (Director) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 LOUMEAU ERIC J (COO, General Counsel) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 60,530 options to buy @ $23.23, valued at $1.4M
Granted 22,180 restricted stock units @ $0
01/10/2023 4 Lizzul Paul F. (Chief Medical Officer) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 67,070 options to buy @ $23.23, valued at $1.6M
Granted 24,580 restricted stock units @ $0
01/10/2023 4 Hamill Laura (Director) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 FENTON DENNIS M (Director) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 10,600 options to buy @ $23.23, valued at $246.2k
Granted 3,900 restricted stock units @ $0
01/10/2023 4 Faga Daniel (Interim CEO) has filed a Form 4 on ANAPTYSBIO, INC
Txns: Granted 194,900 options to buy @ $23.23, valued at $4.5M
Granted 71,400 restricted stock units @ $0
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies",
"Corporate Overview January 2022 Nasdaq: ANAB"
11/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy